CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma.

Exp Hematol Oncol · 2024 · PMC11471030 · PMID 39397022

Europe PMC DOI

hedged sentence

0.0506

closest p · 1.0× alpha

0.0506

boldest claim

The sentences

an increasing trendP = 0.0506so close (0.05 < p ≤ 0.1)

The 2-year overall survival (OS) rate of the patients in the ASCT + CAR-T group also exhibited an increasing trend compared to that of the patients in the CIT group (72.10% vs. 45.38%; P = 0.0506) (Fig. 1 D).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.